Lipoic Acid to Treat Chronic Inflammatory Demyelinating Polyneuropathy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00962429 |
Recruitment Status :
Completed
First Posted : August 20, 2009
Results First Posted : August 19, 2020
Last Update Posted : August 19, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
CIDP Chronic Inflammatory Demyelinating Polyneuropathy | Drug: lipoic acid | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 7 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | Lipoic Acid for Chronic Inflammatory Demyelinating Polyneuropathy-A Randomized, Double-Blind, Placebo Controlled Pilot Study |
Study Start Date : | February 2009 |
Actual Primary Completion Date : | January 2013 |
Actual Study Completion Date : | January 2013 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Lipoic acid
alpha lipoic acid
|
Drug: lipoic acid
Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
Other Name: LA |
Placebo Comparator: Placebo
sugar pill
|
Drug: lipoic acid
Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
Other Name: LA |
- Muscle Strength [ Time Frame: 16 weeks ]
- Hughes Functional Disability Scale [ Time Frame: 16 weeks ]
- Forced Vital Capacity (FVC) [ Time Frame: 16 weeks ]
- Motor Nerve Conduction Studies (NCS) [ Time Frame: 16 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- diagnosis of CIDP
- on a stable dose of immunotherapy for at least 3 months before enrolling in the study
Exclusion Criteria:
- myelopathy or evidence of central demyelination
- persistent neurological deficits from stroke, CNS trauma, or peripheral neuropathy from other causes (eg, diabetes mellitus, IgM, paraproteinaemia, or uraemic, toxic, or familial neuropathy)
- evidence of systemic disease that might cause neuropathy
- heart diseases (congestive heart failure or arrhythmia)
- pulmonary conditions (asthma or CIPD)
- rheumatoid conditions (such as rheumatoid arthritis)
- renal failure

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00962429
United States, Oregon | |
Oregon Health & Science University | |
Portland, Oregon, United States, 97239 |
Principal Investigator: | Jau-Shin Lou, MD, PhD | Oregon Health and Science University |
Responsible Party: | Oregon Health and Science University |
ClinicalTrials.gov Identifier: | NCT00962429 |
Other Study ID Numbers: |
CMT-Lou |
First Posted: | August 20, 2009 Key Record Dates |
Results First Posted: | August 19, 2020 |
Last Update Posted: | August 19, 2020 |
Last Verified: | August 2020 |
neuropathy, lipoic acid |
Polyneuropathies Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Peripheral Nervous System Diseases Neuromuscular Diseases Nervous System Diseases Polyradiculoneuropathy Autoimmune Diseases of the Nervous System Demyelinating Diseases Autoimmune Diseases |
Immune System Diseases Thioctic Acid Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents Physiological Effects of Drugs Vitamin B Complex Vitamins Micronutrients |